Literature DB >> 26867670

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.

S Soverini1, C De Benedittis1, C Papayannidis1, K Machova Polakova2, C Venturi1, D Russo3, P Bresciani4, A Iurlo5, M Mancini1, A Vitale6, S Chiaretti6, R Foà6, E Abruzzese7, F Sorà8, A Kohlmann9, T Haferlach10, M Baccarani1, M Cavo1, G Martinelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26867670     DOI： 10.1038/leu.2016.17

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.

Authors:  J Liu; S Joha; T Idziorek; S Corm; D Hetuin; N Philippe; C Preudhomme; B Quesnel
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

Review 2.  Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

Authors:  M Brüggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cavé; H Dombret; A K Fielding; R Foà; N Gökbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen
Journal:  Leukemia       Date:  2009-12-24       Impact factor: 11.528

3.  Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.

Authors:  Xiaoyan Jiang; Donna Forrest; Franck Nicolini; Ali Turhan; Joelle Guilhot; Calvin Yip; Tessa Holyoake; Heather Jorgensen; Karen Lambie; Kyi Min Saw; Emily Pang; Ranko Vukovic; Paeta Lehn; Ashley Ringrose; Miao Yu; Ryan R Brinkman; Clay Smith; Allen Eaves; Connie Eaves
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

4.  Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.

Authors:  Simona Soverini; Caterina De Benedittis; Cristina Papayannidis; Stefania Paolini; Claudia Venturi; Ilaria Iacobucci; Mario Luppi; Paola Bresciani; Marzia Salvucci; Domenico Russo; Simona Sica; Ester Orlandi; Tamara Intermesoli; Antonella Gozzini; Massimiliano Bonifacio; Gian Matteo Rigolin; Fabrizio Pane; Michele Baccarani; Michele Cavo; Giovanni Martinelli
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

5.  Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.

Authors:  Simona Soverini; Antonella Vitale; Angela Poerio; Alessandra Gnani; Sabrina Colarossi; Ilaria Iacobucci; Giuseppe Cimino; Loredana Elia; Annalisa Lonetti; Marco Vignetti; Stefania Paolini; Giovanna Meloni; Valeria di Maio; Cristina Papayannidis; Marilina Amabile; Anna Guarini; Michele Baccarani; Giovanni Martinelli; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

6.  Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

Authors:  H Pfeifer; T Lange; S Wystub; B Wassmann; J Maier; A Binckebanck; A Giagounidis; M Stelljes; M Schmalzing; U Dührsen; L Wunderle; H Serve; P Brück; A Schmidt; D Hoelzer; O G Ottmann
Journal:  Leukemia       Date:  2012-01-09       Impact factor: 11.528

Review 7.  Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.

Authors:  Josep-Maria Ribera
Journal:  Leuk Lymphoma       Date:  2012-08-13

8.  NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.

Authors:  D M Murphy; R Bejar; K Stevenson; D Neuberg; Y Shi; C Cubrich; K Richardson; P Eastlake; G Garcia-Manero; H Kantarjian; B L Ebert; G Mike Makrigiorgos
Journal:  Leukemia       Date:  2013-05-27       Impact factor: 11.528

Review 9.  Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.

Authors:  Josep-Maria Ribera; Albert Ferrer; Jordi Ribera; Eulàlia Genescà
Journal:  Onco Targets Ther       Date:  2015-06-24       Impact factor: 4.147

10.  Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.

Authors:  J Malcikova; K Stano-Kozubik; B Tichy; B Kantorova; S Pavlova; N Tom; L Radova; J Smardova; F Pardy; M Doubek; Y Brychtova; M Mraz; K Plevova; E Diviskova; A Oltova; J Mayer; S Pospisilova; M Trbusek
Journal:  Leukemia       Date:  2014-10-28       Impact factor: 11.528
View more
  8 in total

1.  Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.

Authors:  Sara De Santis; Margherita Martelli; Cecilia Monaldi; Simona Soverini; Fausto Castagnetti; Gabriele Gugliotta; Cristina Papayannidis; Manuela Mancini; Samantha Bruno; Claudia Venturi; Katerina Machova Polakova; Thomas Ernst; Dianna Maar; Adam Corner; Michele Cavo
Journal:  Leukemia       Date:  2022-07-30       Impact factor: 12.883

Review 2.  P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.

Authors:  Stefania Trino; Luciana De Luca; Ilaria Laurenzana; Antonella Caivano; Luigi Del Vecchio; Giovanni Martinelli; Pellegrino Musto
Journal:  Front Pharmacol       Date:  2016-12-16       Impact factor: 5.810

3.  Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia.

Authors:  H Jonathan G Lindström; Astrid S de Wijn; Ran Friedman
Journal:  BMC Cancer       Date:  2019-05-28       Impact factor: 4.430

4.  Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia.

Authors:  Constance Baer; Manja Meggendorfer; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941

5.  INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.

Authors:  Giovanni Martinelli; Cristina Papayannidis; Alfonso Piciocchi; Valentina Robustelli; Simona Soverini; Carolina Terragna; Giovanni Marconi; Roberto M Lemoli; Fabio Guolo; Antonella Fornaro; Monia Lunghi; Paolo de Fabritiis; Anna Candoni; Carmine Selleri; Federico Simonetti; Monica Bocchia; Antonella Vitale; Luca Frison; Alessandra Tedeschi; Antonio Cuneo; Massimiliano Bonifacio; Maria Paola Martelli; Stefano D'Ardia; Silvia Trappolini; Patrizia Tosi; Piero Galieni; Francesco Fabbiano; Maria Chiara Abbenante; Muriel Granier; Zhaoyin Zhu; Mingyue Wang; Chiara Sartor; Stefania Paolini; Michele Cavo; Robin Foà; Paola Fazi; Marco Vignetti; Michele Baccarani
Journal:  Blood Adv       Date:  2022-03-22

6.  Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.

Authors:  Santiago Barrio; Joaquín Martínez-López; Ricardo Sánchez; Sara Dorado; Yanira Ruíz-Heredia; Alejandro Martín-Muñoz; Juan Manuel Rosa-Rosa; Jordi Ribera; Olga García; Ana Jimenez-Ubieto; Gonzalo Carreño-Tarragona; María Linares; Laura Rufián; Alexandra Juárez; Jaime Carrillo; María José Espino; Mercedes Cáceres; Sara Expósito; Beatriz Cuevas; Raúl Vanegas; Luis Felipe Casado; Anna Torrent; Lurdes Zamora; Santiago Mercadal; Rosa Coll; Marta Cervera; Mireia Morgades; José Ángel Hernández-Rivas; Pilar Bravo; Cristina Serí; Eduardo Anguita; Eva Barragán; Claudia Sargas; Francisca Ferrer-Marín; Jorge Sánchez-Calero; Julián Sevilla; Elena Ruíz; Lucía Villalón; María Del Mar Herráez; Rosalía Riaza; Elena Magro; Juan Luis Steegman; Chongwu Wang; Paula de Toledo; Valentín García-Gutiérrez; Rosa Ayala; Josep-Maria Ribera
Journal:  Sci Rep       Date:  2022-07-29       Impact factor: 4.996

Review 7.  Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.

Authors:  Simona Soverini; Francesco Albano; Renato Bassan; Francesco Fabbiano; Felicetto Ferrara; Robin Foà; Attilio Olivieri; Alessandro Rambaldi; Giuseppe Rossi; Simona Sica; Giorgina Specchia; Adriano Venditti; Giovanni Barosi; Fabrizio Pane
Journal:  Cancer Med       Date:  2020-03-10       Impact factor: 4.452

Review 8.  Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.

Authors:  Sara De Santis; Cecilia Monaldi; Manuela Mancini; Samantha Bruno; Michele Cavo; Simona Soverini
Journal:  Onco Targets Ther       Date:  2022-01-25       Impact factor: 4.147
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.